Larimar Therapeutics, Inc. (NASDAQ:LRMR), with a market capitalization of $228 million, is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases ...

Truist has initiated coverage of Larimar Therapeutics (NASDAQ:LRMR) with a buy rating, citing an "asymmetric" risk/reward ahead of regulatory updates for its drug candidate nomla for Friedreich ...

Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Thursday, March 13th. Analysts expect the company to announce ...

Following the conclusion of the presentation, a replay will be available for 30 days on the “Events and Presentations” page of Larimar’s website.

Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) have been assigned an average recommendation of “Buy” from the eleven brokerages that are presently covering the firm ...

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and ...

Explore Larimar Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for LRMR. Larimar Therapeutics reports promising FXN level increases with 25 mg ...

BALA CYNWYD, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...